FR2964323B1 - Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate - Google Patents

Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate

Info

Publication number
FR2964323B1
FR2964323B1 FR1003574A FR1003574A FR2964323B1 FR 2964323 B1 FR2964323 B1 FR 2964323B1 FR 1003574 A FR1003574 A FR 1003574A FR 1003574 A FR1003574 A FR 1003574A FR 2964323 B1 FR2964323 B1 FR 2964323B1
Authority
FR
France
Prior art keywords
androgenic
testosterone
deficit
patient
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1003574A
Other languages
English (en)
Other versions
FR2964323A1 (fr
Inventor
Jean Pierre Raynaud
Henri Botto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR1003574A priority Critical patent/FR2964323B1/fr
Publication of FR2964323A1 publication Critical patent/FR2964323A1/fr
Application granted granted Critical
Publication of FR2964323B1 publication Critical patent/FR2964323B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR1003574A 2010-09-08 2010-09-08 Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate Expired - Fee Related FR2964323B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1003574A FR2964323B1 (fr) 2010-09-08 2010-09-08 Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1003574A FR2964323B1 (fr) 2010-09-08 2010-09-08 Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate

Publications (2)

Publication Number Publication Date
FR2964323A1 FR2964323A1 (fr) 2012-03-09
FR2964323B1 true FR2964323B1 (fr) 2012-11-09

Family

ID=43901416

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1003574A Expired - Fee Related FR2964323B1 (fr) 2010-09-08 2010-09-08 Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate

Country Status (1)

Country Link
FR (1) FR2964323B1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015123617A1 (fr) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Procédé pour réduire l'expression du gène bcl2
DE102014005513B4 (de) * 2014-04-15 2018-03-15 Sanoxsys Gmbh Mittel zur Prävention und Therapie von Tumorerkrankungen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235808A1 (en) * 2001-09-21 2004-11-25 Jiabing Wang Androstanes as androgen receptor modulators
US20070167418A1 (en) * 2004-09-07 2007-07-19 Ferguson Steven W Progesterone/testosterone cream for erectile dysfunction
EP1896038B1 (fr) * 2005-06-03 2016-11-09 Acrux DDS Pty Ltd Methode et composition pour l'administration transdermique de la testosterone
EP1854465A1 (fr) * 2006-05-12 2007-11-14 Alexander Tobias Teichmann Utilisation du 4,17 béta-dihydroxyandrost-4-ene-3-one pour traiter les cancers
ES2547339T3 (es) * 2007-11-13 2015-10-05 Curadis Gmbh Esteroides C-19 para usos terapéuticos específicos
TWI442932B (zh) * 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
WO2010085511A1 (fr) * 2009-01-21 2010-07-29 Glaxosmithkline Llc Procédé de traitement d'un cancer de la prostate

Also Published As

Publication number Publication date
FR2964323A1 (fr) 2012-03-09

Similar Documents

Publication Publication Date Title
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
EP2620026A4 (fr) Relayage dans le regroupement mixte de porteuses réglementées et non réglementées
IL219992A0 (en) Combination therapy for treating cancer and dianostic assays for use therein
IL258794B (en) Methods and compositions for diagnosis and treatment of cancer
PT2619576T (pt) Meios e métodos para a previsão de resposta ao tratamento de um paciente com cancro
HRP20160714T1 (hr) Sredstva za induciranje apoptoze namijenjena liječenju raka i imunih i autoimunih bolesti
EP2542245A4 (fr) Stéroïdes cationiques antimicrobiens et procédés d'utilisation
PL2544680T3 (pl) Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego
PL2598531T3 (pl) Sposoby i kompozycje do terapii nowotworu wątroby
EP2648583A4 (fr) Pot et accouplement de mixeur
IL236482A0 (en) Use of markers in the diagnosis and treatment of prostate cancer
GB201005294D0 (en) Liquid distribution and metering
IL251083B (en) Compounds and compositions for the treatment of cancer
ZA201205432B (en) Compositions and methods for the diagnosis and treatment of tumor
PL2426148T3 (pl) Przeciwciało anty-IL-3RA do stosowania w leczeniu nowotworu krwi
EP2659004A4 (fr) Modulation de la dynéine dans la peau
AP3480A (en) Phosphaplatins and their use for treatment of cancers
AU332151S (en) Planter
EP2651894A4 (fr) Composés de thiosemicarbazone et utilisation dans le traitement du cancer
GB201011411D0 (en) Therapeutic compounds and their use
IL227687B (en) Anti-alpha-v integrin antibody for use in the treatment of prostate cancer
EP2575863A4 (fr) Utilisation de la signature du microenvironnement des sparc dans le traitement du cancer
ZA201202657B (en) Use of the sparc microenvironment signature in the treatment of cancer
IL224632A (en) Fentanyl docushexanavate and its use in the treatment and prevention of cardiovascular disease
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 12

ST Notification of lapse

Effective date: 20210505

RN Application for restoration

Effective date: 20210610

FC Decision of inpi director general to approve request for restoration

Effective date: 20210623

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

ST Notification of lapse

Effective date: 20250505